CD38, A Target for Immunotherapeutic Approaches in Cancer
Cells | Free Full-Text | Novel Insights in Anti-CD38 Therapy Based on CD38-Receptor Expression and Function: The Multiple Myeloma Model
Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab | Leukemia
CD38 expression and function in NK cells. (A) Role of CD38 in the... | Download Scientific Diagram
![PDF] Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/72ce80f2da87d037624955a597846d530a0c6052/3-Figure1-1.png "PDF] Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma | Semantic Scholar")
PDF] Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma | Semantic Scholar
Cells | Free Full-Text | CD38 Expression by Myeloma Cells and Its Role in the Context of Bone Marrow Microenvironment: Modulation by Therapeutic Agents
Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab | Leukemia
Double CD38−/CD138− negative multiple myeloma - ScienceDirect
Cureus | CD38: From Positive to Negative Expression after Daratumumab Treatment | Article
![Annotating CD38 Expression in Multiple Myeloma with [18F]F–Nb1053 | Molecular Pharmaceutics](https://pubs.acs.org/cms/10.1021/acs.molpharmaceut.1c00733/asset/images/acs.molpharmaceut.1c00733.social.jpeg_v03 "Annotating CD38 Expression in Multiple Myeloma with [18F]F–Nb1053 | Molecular Pharmaceutics")
Annotating CD38 Expression in Multiple Myeloma with [18F]F–Nb1053 | Molecular Pharmaceutics
CD38 directed therapies for management of multiple myeloma | ITT
Mechanism of Action of a New Anti-CD38 Antibody: Enhancing Myeloma Immunotherapy | Semantic Scholar
International Clinical Cytometry Society
Expression of CD38 in myeloma bone niche: A rational basis for the use of anti-CD38 immunotherapy to inhibit osteoclast formatio
Frontiers | Daratumumab for the Treatment of Multiple Myeloma
Pre-treatment CD38-positive regulatory T cells affect the durable response to daratumumab in relapsed/refractory multiple myeloma patients | Haematologica
A Guide to Plasma Cell Markers | Biocompare: The Buyer's Guide for Life Scientists
Regulation of CD38 on Multiple Myeloma and NK Cells by Monoclonal Antibodies
Anti-CD38 antibody therapy for patients with relapsed/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomes | SpringerLink
Expression of CD38 in normal and malignant plasma cells.... | Download Scientific Diagram
Cells | Free Full-Text | The Many Facets of CD38 in Lymphoma: From Tumor–Microenvironment Cell Interactions to Acquired Resistance to Immunotherapy
CD38, A Target for Immunotherapeutic Approaches in Cancer
